(Q50581322)

15 March 2018

http://europepmc.org/abstract/MED/26101071

title

Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. (English)

1 reference

15 March 2018

http://europepmc.org/abstract/MED/26101071

author

Carolyn A. Young

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26101071%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Neil Scolding

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26101071%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

8

David Miller

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26101071%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

David Barnes

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26101071%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Sarah Cader

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26101071%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Jeremy Chataway

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26101071%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Abhijit Chaudhuri

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26101071%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Alasdair Coles

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26101071%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Gavin Giovannoni

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26101071%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Waqar Rashid

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26101071%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Klaus Schmierer

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26101071%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Abdullah Shehu

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26101071%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Eli Silber

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26101071%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

John Zajicek

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26101071%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

publication date

22 June 2015

1 reference

15 March 2018

http://europepmc.org/abstract/MED/26101071

published in

Practical Neurology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26101071%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26101071%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26101071%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

273-279

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26101071%20AND%20SRC:MED&resulttype=core&format=json

Disease modification in multiple sclerosis: an update

13 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139

Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139

Scoring treatment response in patients with relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139

A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139

Early Relapses, Onset of Progression, and Late Outcome in Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FPRACTNEUROL-2015-001139